TransMedics Gr Q2 EPS $0.35 Beats $0.21 Estimate, Sales $114.31M Beat $98.97M Estimate
Portfolio Pulse from Benzinga Newsdesk
TransMedics Group (NASDAQ:TMDX) reported strong Q2 earnings, with EPS of $0.35 beating the $0.21 estimate and sales of $114.31M surpassing the $98.97M estimate. This marks a significant improvement from the same period last year.
July 31, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransMedics Group reported Q2 EPS of $0.35, beating the $0.21 estimate by 66.67%. Sales were $114.31M, surpassing the $98.97M estimate by 15.49%. This represents a significant improvement from the same period last year.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year improvement, is likely to positively impact TMDX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100